EDAP TMS S.A. (FOCL) - Total Liabilities

Latest as of June 2026: $77.77 Million USD

Based on the latest financial reports, EDAP TMS S.A. (FOCL) has total liabilities worth $77.77 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check EDAP TMS S.A. (FOCL) asset resilience to evaluate the company's liquid asset resilience ratio.

EDAP TMS S.A. - Total Liabilities Trend (2006–2025)

This chart illustrates how EDAP TMS S.A.'s total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see EDAP TMS S.A. (FOCL) total assets.

EDAP TMS S.A. Competitors by Total Liabilities

The table below lists competitors of EDAP TMS S.A. ranked by their total liabilities.

Company Country Total Liabilities
Mega Uranium Ltd.
TO:MGA
Canada CA$34.20 Million
Chant Sincere Co Ltd
TW:6205
Taiwan NT$1.14 Billion
St.Shine Optical Co Ltd
TWO:1565
Taiwan NT$1.26 Billion
BBMG Corporation
F:9BM
Germany €174.70 Billion
Brazil Potash Corp.
NYSE:GRO
USA $15.37 Million
Atp Ticari Bilgisayar Agi ve Elektrik Guc Kaynaklari Uretim Pazarlama ve Ticaret
IS:ATATP
Turkey TL633.82 Million
JIUMAOJIU INTL HLDGS LTD
F:3YU
Germany €2.61 Billion
Amrutanjan Health Care Limited
NSE:AMRUTANJAN
India Rs902.90 Million

Liability Composition Analysis (2006–2025)

This chart breaks down EDAP TMS S.A.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See EDAP TMS S.A. balance sheet independence to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.60 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity -24.12 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 1.04 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how EDAP TMS S.A.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for EDAP TMS S.A. (2006–2025)

The table below shows the annual total liabilities of EDAP TMS S.A. from 2006 to 2025.

Year Total Liabilities Change
2025-12-31 $59.58 Million +27.40%
2024-12-31 $46.77 Million +22.28%
2023-12-31 $38.25 Million +21.53%
2022-12-31 $31.47 Million +1.86%
2021-12-31 $30.90 Million -9.31%
2020-12-31 $34.07 Million +23.20%
2019-12-31 $27.66 Million +6.40%
2018-12-31 $25.99 Million +4.57%
2017-12-31 $24.86 Million +7.59%
2016-12-31 $23.10 Million -11.07%
2015-12-31 $25.98 Million +27.23%
2014-12-31 $20.42 Million -15.76%
2013-12-31 $24.24 Million -17.50%
2012-12-31 $29.38 Million -3.80%
2011-12-31 $30.54 Million -15.81%
2010-12-31 $36.27 Million -9.06%
2009-12-31 $39.88 Million +7.58%
2008-12-31 $37.08 Million -16.87%
2007-12-31 $44.60 Million +156.75%
2006-12-31 $17.37 Million --

About EDAP TMS S.A.

NASDAQ:FOCL USA Medical Distribution
Market Cap
$153.11 Million
Market Cap Rank
#17650 Global
#4169 in USA
Share Price
$4.08
Change (1 day)
-0.73%
52-Week Range
$4.08 - $6.34
All Time High
$6.34
About

EDAP TMS S.A., doing business as FocalTherics, operates as a medical technology company that develops, manufactures, markets, and sells non-invasive therapeutic ultrasound and energy-based medical devices in Asia, France, the United States, and internationally. The company develops, manufactures, markets, and distributes non-invasive robotic HIFU systems for urology-related and other indications.… Read more